Skip to main content

Table 1 Clinical inputs parameter estimates

From: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

Parameter

Annual probabilities

Non-prophylaxis

Source

Palivizumab

Source

Probability of hospital admission due RSV infection

 Total population

4.10%

[14]

1.30%

[14]

 Subgroup A

18.40%

[33]

9.50%

[33]

 Subgroup B

10.60%

3.60%

 Subgroup C

10.20%

2.90%

Probability of emergency visits prior to hospital admission

 

17.80%

[14]

17.80%

[14]

Probability of death related to hospital admission

 

2.33%

[3]

2.33%

[3]

Probability of additional hospitalizations due to new RSV infection

 

2.47%

[14]

2.47%

[14]

Probability of recurrent wheezing in hospitalized patients.

 Year 2

41.43%

[15]

18.43%

[15]

 Year 3

29.27%

11.05%

 Year 4

18.55%

6.12%

 Year 5

15.00%

4.39%

 Year 6

12.39%

3.25%

Probability of recurrent wheeze in no-hospitalized patients

 Year 2

12.09%

[15]

5.38%

[15]

 Year 3

15.36%

5.80%

 Year 4

12.57%

4.15%

 Year 5

9.31%

2.73%

 Year 6

9.66%

2.53%

  1. Subgroup A includes preterm infants with 2 major risk factors and 2 minor risk factors; subgroup B, 2 major risk factors and 1 minor risk factors; subgroup C, 2 major risk factors [33]
  2. Major factors: chronological age less than 10 weeks at the beginning of RSV season or being born during the first 10 weeks of the season; school-age siblings or day-care attendance. Minor factors: mother smoking during pregnancy and male gender